Akshat Malik1, Burhanuddin N Qayyumi1, Manish Mair1, Hitesh Singhavi1, Yash Mathur1, Deepa Nair1, Sarbani Ghosh-Laskar2, Jai Prakash Agrawal2, Kumar Prabash3, Pankaj Chaturvedi4. 1. Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India. 2. Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India. 3. Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India. 4. Department of Head and Neck Surgical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Dr. E Borges Road, Parel, Mumbai, 400012, India. chaturvedi.pankaj@gmail.com.
Abstract
BACKGROUND: This study was undertaken to assess the effects of neo-adjuvant chemotherapy (NACT) on patients with head and neck squamous cell carcinoma (HNSCC) having advanced unresectable cervical nodal metastasis. METHODOLOGY: A retrospective cohort study was conducted to assess the response of unresectable nodes to NACT in a pragmatic manner. Patients were grouped according to the response noted and the treatment offered after chemotherapy. The median survival amongst the patients in these groups was compared. RESULTS: The study included 51 patients. Oral cavity was the commonest site (67.2%). Favourable nodal response was seen in 64.7% of the patients. Up to 87.9% of the nodal responders were amenable to curative intent therapy. The overall survival of patients undergoing surgery, definitive chemoradiotherapy, palliative chemotherapy and palliative radiotherapy was 24, 13, 10 and 9 months, respectively. CONCLUSION: NACT may be utilized in HNSCC with advanced inoperable nodal disease to make them amenable to definitive therapy.
BACKGROUND: This study was undertaken to assess the effects of neo-adjuvant chemotherapy (NACT) on patients with head and neck squamous cell carcinoma (HNSCC) having advanced unresectable cervical nodal metastasis. METHODOLOGY: A retrospective cohort study was conducted to assess the response of unresectable nodes to NACT in a pragmatic manner. Patients were grouped according to the response noted and the treatment offered after chemotherapy. The median survival amongst the patients in these groups was compared. RESULTS: The study included 51 patients. Oral cavity was the commonest site (67.2%). Favourable nodal response was seen in 64.7% of the patients. Up to 87.9% of the nodal responders were amenable to curative intent therapy. The overall survival of patients undergoing surgery, definitive chemoradiotherapy, palliative chemotherapy and palliative radiotherapy was 24, 13, 10 and 9 months, respectively. CONCLUSION:NACT may be utilized in HNSCC with advanced inoperable nodal disease to make them amenable to definitive therapy.
Entities:
Keywords:
Head and neck cancers; Induction chemotherapy; Response; Unresectable nodes
Authors: Arlene A Forastiere; Kie-Kian Ang; David Brizel; Bruce E Brockstein; Barbara A Burtness; Anthony J Cmelak; Alexander D Colevas; Frank Dunphy; David W Eisele; Helmuth Goepfert; Wesley L Hicks; Merrill S Kies; William M Lydiatt; Ellie Maghami; Renato Martins; Thomas McCaffrey; Bharat B Mittal; David G Pfister; Harlan A Pinto; Marshall R Posner; John A Ridge; Sandeep Samant; David E Schuller; Jatin P Shah; Sharon Spencer; Andy Trotti; Randal S Weber; Gregory T Wolf; Frank Worden Journal: J Natl Compr Canc Netw Date: 2008-08 Impact factor: 11.908
Authors: Huaising C Ko; Shuai Chen; Aaron M Wieland; Menggang Yu; Andrew M Baschnagel; Gregory K Hartig; Paul M Harari; Matthew E Witek Journal: Head Neck Date: 2017-07-24 Impact factor: 3.147
Authors: Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner Journal: Lancet Oncol Date: 2013-02-13 Impact factor: 41.316
Authors: J-L Lefebvre; G Andry; D Chevalier; B Luboinski; L Collette; L Traissac; D de Raucourt; J A Langendijk Journal: Ann Oncol Date: 2012-04-06 Impact factor: 32.976
Authors: Jessica K Smyth; Allison M Deal; Benjamin Huang; Mark Weissler; Adam Zanation; Carol Shores Journal: Laryngoscope Date: 2011-09 Impact factor: 3.325
Authors: June Corry; Lester Peters; Richard Fisher; Andrew Macann; Michael Jackson; Bev McClure; Danny Rischin Journal: Head Neck Date: 2008-06 Impact factor: 3.147
Authors: Lawrence H Schwartz; Saskia Litière; Elisabeth de Vries; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Lesley Seymour Journal: Eur J Cancer Date: 2016-05-14 Impact factor: 9.162
Authors: Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre Journal: N Engl J Med Date: 2007-10-25 Impact factor: 91.245